pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,640 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1565Endpoints1225BioSpace565Fierce Biotech562BioPharma Dive467raps192onclive165fda recalls103
therapy area
allOncology10451Rare Disease2757Immunology2463Cardiology2287Hematology1887Pulmonology1875Vaccines
  • House lawmakers hear mixed views on credentialing for psychedelic providers
    As psychedelic medicines move closer to market, two members of the U.S. House are outlining how the drugs might be rolled out and what accompanying legislation could look like. The focus of their…
    Endpoints · 20d agoRegulatoryNeutral↗ source
  • Podcast examines growing US mistrust in science and a new gene-editing lawsuit
    The latest episode of The Readout LOUD, a weekly biotech podcast, focused on the erosion of public confidence in science. Hosts Adam Feuerstein, Elaine Chen, and Allison DeAngelis spoke with STAT’…
    STAT · 20d agoNeutral↗ source
← prev
page 21 of 146
next →
fda medwatch93
globenewswire health73
fda press54
1646
Psychiatry & CNS1107
Ophthalmology871
Endocrinology & Metabolism691
Pain656
Nephrology645
  • CDC plans to drop disability questions from health survey, sparking concerns of undercounting
    The Centers for Disease Control and Prevention is proposing a redesign of the National Health Interview Survey that would eliminate questions about disabilities. The change is part of a broader eff…
    STAT · 20d agoRegulatoryNegative↗ source
  • BioSpace lists top 12 biopharma employers hiring in July 2026
    BioSpace released a list of the twelve biopharma firms with the most job postings in July 2026. The list includes AbbVie, Regeneron, Amgen, Eli Lilly, Sanofi, Novo Nordisk, Moderna, Insmed, Freder…
    BioSpace · 20d agoNeutral↗ source
  • Biopharma job seekers urged to act quickly in Q4 hiring surge
    Biopharma professionals face a busy fourth‑quarter hiring season, and experts say candidates should submit applications as soon as possible rather than waiting. Angie Allen, managing partner at Ka…
    BioSpace · 20d agoPositive↗ source
  • Trump administration appeals court decision that blocks limits on international student and postdoc visas
    The Department of Homeland Security has filed an appeal after a federal judge ruled that the agency cannot impose new restrictions on how long international students and postdoctoral researchers ma…
    STAT · 20d agoRegulatoryNeutral↗ source
  • STAT+: MAHA goes corporate
    Health care companies dominate the MAHA Summit, and a look at Trump's watered down effort to lower Medicare drug prices.
    STAT · 20d ago↗ source
  • Sanofi pays Regeneron $1B upfront to continue search for Dupixent successor
    Sanofi and Regeneron have had a long and “sometimes contentious” partnership, BMO Capital Markets noted, as the companies contend with the looming loss of exclusivity of their blockbuster drug Dupi…
    BioSpace · 20d ago↗ source
  • Lilly’s EloraTZP combo shows superior weight loss and glucose control, moves to Phase 3
    Eli Lilly reported that its experimental combination, EloraTZP, which pairs an amylin agonist with the approved obesity drug Zepbound, met all primary and secondary goals in a mid‑stage study of ad…
    BioSpace · 21d agoPositive readoutPositive↗ source
  • Eli Lilly’s Zepbound plus amylin candidate shows 23% weight loss in phase 2 trial, but many patients stopped treatment
    Eli Lilly tested a combination of its GLP‑1 obesity drug Zepbound with the amylin‑targeting candidate eloralintide in a mid‑stage study of people with obesity and type 2 diabetes. After 48 weeks,…
    STAT · 21d agoPositive readoutNeutral↗ source
  • UnitedHealth lawsuit proceeds as judge rejects motion to dismiss earnings manipulation claims
    A federal judge allowed an investor lawsuit against UnitedHealth Group to continue, rejecting the company's request to throw out the case. The suit alleges UnitedHealth inflated its 2024 earnings…
    STAT · 20d agoRegulatoryNegative↗ source
  • Merck reports positive mid-stage results for Prometheus' tulisokibart in painful skin disease
    Merck presented new data from a mid-stage trial of tulisokibart, a drug acquired through its $10.8 billion purchase of Prometheus Biosciences. The trial evaluated multiple dose levels in patients…
    Endpoints · 21d agoPositive readoutPositive↗ source
  • Trump administration's final Medicare pricing rule limits savings, covering only four firms
    The Trump administration released a final rule intended to lower Medicare prices for drugs administered in physician offices. The rule is part of the Global Benchmark for Efficient Drug Pricing (GL…
    STAT · 20d agoRegulatoryNegative↗ source
  • HHS launches SURPASS program to accelerate clinical trials using AI and adaptive designs
    HHS announced a new five-year initiative called SURPASS, aimed at speeding up and expanding clinical trials by leveraging artificial intelligence and computational modeling. The program, run throu…
    STAT · 21d agoRegulatoryPositive↗ source
  • Patient death raises safety concerns before Bristol Myers lung drug readout
    A patient died from a fatal liver injury while taking part in a trial of Bristol Myers Squibb's lung disease candidate. The company disclosed the incident in a May amendment to its trial documents…
    Endpoints · 21d agoNegative↗ source
  • U.S. plan to cut Medicaid for legal immigrants, including refugees and trafficking victims, takes effect Oct. 1
    Hundreds of thousands of lawfully present immigrants could lose Medicaid coverage beginning Oct. 1, according to state data. The change is part of the One Big Beautiful Bill Act, a Republican effor…
    STAT · 21d agoRegulatoryNegative↗ source
  • Varda Space Industries secures $251 million Series D to develop drug manufacturing in orbit
    California startup Varda Space Industries announced it has closed a $251 million Series D financing round. The capital will be directed toward building and launching manufacturing facilities in lo…
    Endpoints · 21d agoDealPositive↗ source
  • Atara and Pierre Fabre resubmit Ebvallo cell therapy after second FDA rejection
    Atara Biotherapeutics and Pierre Fabre Pharmaceuticals have filed a new FDA submission for their cell therapy candidate Ebvallo (tabelecleucel), aimed at treating Epstein‑Barr virus‑positive post‑t…
    BioSpace · 21d agoRegulatoryNeutral↗ source
  • Lilly's amylin-Zepbound combo shows up to 23.3% weight loss in obesity-diabetes patients at EASD 2026
    Lilly presented new data on its amylin‑Zepbound combination at the European Association for the Study of Diabetes meeting in Milan. The trial focused on patients who have both obesity and type 2 di…
    Endpoints · 21d agoPositive readoutPositive↗ source
  • Poll finds most rural MAHA supporters say Trump health policies have not improved community health
    A new Associated Press‑KFF poll of more than 2,000 rural registered voters shows that while about half of respondents identify with the Make America Healthy Again (MAHA) movement, roughly eight in…
    STAT · 21d agoNegative↗ source
  • Beam sues over alleged IP theft as Moderna appoints new COO and Pierre Fabre/Atara refile drug for ultra-rare blood cancer
    Beam Therapeutics has filed a lawsuit claiming a former scientist took proprietary information and used it to start a Chinese firm, alleging theft of its intellectual property. PhRMA announced a n…
    STAT · 21d agoRegulatoryNeutral↗ source
  • Lilly uses indirect data to argue its oral GLP-1 pill may outperform Novo’s semaglutide
    Eli Lilly’s weight‑loss drug Foundayo has seen a slower launch than expected, according to BMO Capital Markets, which noted the product is lagging behind competitors. To bolster its market case, L…
    BioSpace · 21d agoPositive readoutNeutral↗ source
  • AstraZeneca invests $2 billion in Summit Therapeutics as uniQure shares tumble on disappointing Huntington’s data
    Summit Therapeutics received a $2 billion all‑stock investment from AstraZeneca aimed at advancing its bispecific antibody ivonescimab through late‑stage trials. The funding is expected to support…
    BioSpace · 21d agoDealNeutral↗ source
  • US must strengthen its biotech sector to stay ahead of China, authors argue
    Gary Locke and Patrick McHenry, former U.S. officials and senior advisers to the American Biosecurity Initiative, argue that the United States must invest in its own biotech capabilities to preserv…
    STAT · 21d agoPositive↗ source
  • FDA seeks new advisory committee members, signaling renewed focus on external expertise
    The FDA announced it is inviting subject‑matter experts and consumer representatives to serve on its advisory committees. The call follows a period when the advisory committees had a reduced role…
    raps · 21d agoRegulatoryNeutral↗ source